Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Understanding when and how to adjust a zero based budget helps you stay aligned with goals. Explore timing, methods, and best practices.
28,655 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
NVIDIA stakes its AI dominance on data center hardware while Palantir expands software driven growth, setting up a hi...
Binance’s delisting of five smaller tokens sparked a brutal price collapse altcoins, with double-digit losses across ...
AI-related debt now accounts for about 15% of the debt corporate bond market, signaling a shift that could alter risk...
As IPO risk rises in 2026, Altria’s reliable 6% dividend and decades of payout growth position it as a steadier optio...
Bitcoin again hovers near the 70K mark as XRP mirrors BTC moves. A test of AI forecasting asks what XRP bottoms could...
In 2026, corporate bond spreads tightening is reshaping risk and return for the iShares LQD ETF, as yields, credit qu...
A fresh Wall Street call boosts Broadcom stock, signaling a potential historic buy as AI chip demand and a multi-year...
Bitcoin Policy UK rebuked Michael Saylor’s STRC investment promotion as dishonest marketing. The clash highlights gro...
Netflix falls on growth and valuation concerns while iHeartMedia rises on an expanded podcast partnership. The move h...
Oracle's AI strategy is under scrutiny as earnings shed light on backlog and cash needs. We see roughly 46-47% upside...
A fresh analysis shows WisdomTree's WCLD underperforms due to equal-weight rebalancing, turning a $10,000 stake into ...